Since the publication with the February 2022 compounding threat alert, FDA is now aware about expanding public curiosity in using sublingual and oral dosage forms of compounded ketamine for your treatment of psychiatric disorders. FDA understands that the chance to receive these solutions via telemedicine platforms and compounders for at-house https://ketalinic.com/ketamine-powder-nasal-spray-vials/